Figure 3 E, were treated with ASPD (32 nM) for 6 hr. The ratio of eNOS-P-Thr 495 to eNOS-total was obtained as in C (n = 3). Data are presented as means ± S.E. ∗ P < 0.05/∗∗ P < 0.01 (ANOVA with Scheffé’s method). " width="100%" height="100%">
Journal: iScience
Article Title: Alzheimer's Aβ assembly binds sodium pump and blocks endothelial NOS activity via ROS-PKC pathway in brain vascular endothelial cells
doi: 10.1016/j.isci.2021.102936
Figure Lengend Snippet: ASPD-NAKα3 interaction in caveolae increases the phosphorylation of eNOS-Thr 495 in primary human cerebral endothelial cells (A) Primary human brain microvessel endothelial cells, treated with ASPD at the indicated concentration for 0, 10, or 60 min, were multiply stained with the indicated antibodies; NAKα3-specific antibody, eNOS-specific antibody, lipid rafts flotillin-1-specific antibody, and ASPD-specific antibody (rabbit polyclonal rpASD1), along with DAPI nuclear stain, were used as described in “ ”. The weighted colocalization coefficients were obtained using ZEN2009 software (the eNOS-overlapped NAKα3/total NAKα3 ratios in the cells treated with ASPD for 0, 10, and 60 min are 55.7 ± 2.4%, 58.8 ± 4.8%, and 56.0 ± 2.4%, respectively; the NAKα3-overlapped eNOS/total eNOS ratios in the cells treated with ASPD for 0, 10, and 60 min are 40.8 ± 1.4%, 42.7 ± 2.1%, and 40.1 ± 1.7%, respectively; the flotillin-1-overlapped NAKα3/total NAKα3 ratios in the cells treated with ASPD for 0, 10, and 60 min are 4.5 ± 0.9%, 4.9 ± 1.2%, and 3.6 ± 0.9%, respectively: data are presented as means ± S.E. (n = 10)) (see “ ”). The weighted colocalization coefficients represent the number of red (or green) pixels that co-localize with green (or red) pixels divided by the total number of red (or green) pixels. Scale bars: 5 μm for solid line and 1 μm for hatched line. (B) Schematic illustration of the relationship between the NO production and the phosphorylation at Ser 1177 /Thr 495 of eNOS. Carbachol activates eNOS by inducing phosphorylation at Ser 1177 and dephosphorylation at Thr 495 in parallel (green arrows). ASPD increase Thr 495 phosphorylation of eNOS (red arrow) through an independent pathway from that of carbachol. (C) Primary human endothelial cells were treated with ASPD (35 nM) for 6 hr (see “ ”). The levels of eNOS-P-Ser 1177 , eNOS-P-Thr 495 , and eNOS-total were determined by Western blotting of total extracts with antibodies specific for eNOS-P-Ser 1177 , eNOS-P-Thr 495 , and eNOS-total, respectively, as shown in upper Western blots (see “ ”). Quantification data were determined by densitometry using LAS-4000 Mini software and are shown as the ratio of eNOS-P-Ser 1177 or eNOS-P-Thr 495 to eNOS-total. The ratio of non-treated cells is shown as 100 (n = 4). Data are presented as means ± S.E. (Welch’s t -test). (D) The endothelial cells were pretreated with ASPD (32 nM) for 6 hr and were further treated with carbachol (1 μM) for 5 min (see “ ”). The ratio of eNOS-P-Ser 1177 to eNOS-total was obtained and is shown as in C (n = 4). Data are presented as means ± S.E. ∗ P < 0.05/∗∗ P < 0.01 (ANOVA with Scheffé’s method). (E) The endothelial cells, with ATP1A3 siRNA or Mock siRNA transfection or without transfection as in Figure 3 E, were treated with ASPD (32 nM) for 6 hr. The ratio of eNOS-P-Thr 495 to eNOS-total was obtained as in C (n = 3). Data are presented as means ± S.E. ∗ P < 0.05/∗∗ P < 0.01 (ANOVA with Scheffé’s method).
Article Snippet: After the incubation, the sections were further incubated with primary antibody against NAKα3 (ANP-003, 1:200; Alomone Labs, Jerusalem, Israel) and von Willebrand factor glycoprotein (sc-365712, 1:50; Santa Cruz Biotechnology, Dallas, TX), and then incubated with the appropriate secondary antibodies (see above).
Techniques: Concentration Assay, Staining, Software, De-Phosphorylation Assay, Western Blot, Transfection